Attendee search 

Relaxbirth Ltd. is an innovative MedTech company, presenting a unique, (r)evolutionary all-in-one solution for childbirths.

Our user-centered innovation consists of the CE-marked and patented Relaxbirth® birthing support device, method and services. Relaxbirth is culturally independent, suitable for different traditions.

Relaxbirth was awarded the Best European Woman Innovation 2009 and the Red Herring 2012 Top 100 Europe and Global Winner, among others.

A committed management team, currently consisting of shareholders, is backed by an International Business Management Advisory Board.

Our mission is to provide wellbeing and positive experiences in childbirth, globally.

Excellent feedback from Relaxbirth mothers offers a strong PR advantage also for hospitals and private clinics.

To sum up our business mission, our slogan is: Celebrate Life®!

Relaxbirth® improves the childbirth process and experience for mothers and personnel. It allows women in labour to make best use of their own bodies and to maximize their power to give birth.

Physiologically, using Relaxbirth gives more space to the birthing canal and also diminishes muscular resistance for the baby to be born.

Psychologically, the feedback shows that using Relaxbirth gives a feeling of empowerment: it increases the possibilities to choose among different birthing positions, in addition to the feeling of being in control of one’s own labour.

From the maternity hospitals’ point of view, Relaxbirth helps improve customer satisfaction and provides a strategic competitive edge. Relaxbirth is an answer to individual needs in labour. Relaxbirth® may also help reduce costs and overcome many current challenges related to childbirth.

Management consulting services for life science and medical technology companies

Medxense offers accurate continuous glucose monitoring for the intensive care unit (ICU). Normalization of patient blood glucose allows hospitals to reduce mortality and patient length of stay. 

The patented sensor technology platform is the only in the field to offer both high accuracy and near-instantaneous measurements in the hypoglycemic range, necessary for safe normalization of blood glucose.

We are now looking for an investment of 3 MUSD to fund clinical trials in the 2nd half of 2014. Expected exits are trade sale or IPO.